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BACKGROUND: Prognosis of localised gastrointestinal stromal tumour (GIST) is heterogeneous, notably for patients with AFIP
intermediate or high risk of relapse, who are candidates to adjuvant imatinib. We hypothesised that gene expression profiles might
improve the prognostication and help to refine the indications for imatinib.
METHODS: We collected gene expression and histoclinical data of 146 pre-treatment localised GIST samples treated with surgery
alone. We searched for a gene expression signature (GES) predictive for relapse-free survival (RFS) and compared its performances
to that of three published prognostic proliferation-based GES (Genomic Grade Index (GGI), 16-Kinase, and CINSARC) and AFIP
classification. We also analysed a data set from 28 patients with advanced GIST treated with neo-adjuvant imatinib.
RESULTS: We identified a 275-gene GES (gene expression signature) predictive of RFS in a learning set and validated its robustness in
an independent set. However, the GGI outperformed its prognostic performances, and those of the two other signatures and the
AFIP intermediate-risk classification in two independent tests sets in uni- and multivariate analyses. Importantly, GGI could split the
AFIP intermediate/high-risk samples into two groups with different RFS. Genomic Grade Index ‘high-risk’ tumours were more
proliferative and genetically unstable than ‘low-risk’ tumours, and more sensitive to imatinib.
CONCLUSION: GGI refines the prediction of RFS in localised GIST and might help tailor adjuvant imatinib.
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Gastrointestinal stromal tumours (GISTs) are the most frequent
mesenchymal digestive tumours (Kitamura et al, 2003; Corless
et al, 2011). Characterised by activating KIT or PDGFRA
mutations, which rend them sensitive to tyrosine kinase inhibitors
(imatinib and sunitinib), they represent a model for molecular-
based diagnosis (West et al, 2004) and treatment (Antonescu, 2011;
Joensuu and Dematteo, 2012). The mainstay of treatment for
localised tumour is complete surgical resection (Casali and Blay,
2010). However, the postoperative clinical outcome is hetero-
geneous, and 20–40% of patients will relapse. KIT and PDGFRA
mutations are early molecular events in GIST development, but
those that accumulate during the disease progression are poorly
elucidated. The current prognostic criteria – anatomical site,
pathological tumour size, mitotic count and tumour rupture
(Dematteo et al, 2008; Casali and Blay, 2010) – are combined in
several risk classifications: NIH 2002 (Fletcher et al, 2002), AFIP
2007 (Miettinen and Lasota, 2006), and Joensuu’s classification
(Joensuu, 2008). Based on recent studies (Dematteo et al, 2009;
Joensuu et al, 2011), adjuvant imatinib is recommended for
patients with ‘substantial risk of relapse’ according to ESMO
guidelines and with ‘intermediate to high risk’ according to AFIP.
In Europe, the AFIP classification is widely used. However, the
2-year relapse-free survival (RFS) without adjuvant imatinib is
close to 75% in the AFIP intermediate-risk patients and 50% in the
high-risk patients (Dematteo et al, 2009), meaning that many of
them are in fact cured by surgery alone.
Today, the imperfection of these risk stratification systems
imposes to refine them to better tailor adjuvant treatment (Patel,
2011). The knowledge of molecular alterations may help achieve
this. Prognostic value has been associated with the type of KIT/
PDGFRA mutation (Heinrich et al, 2008a, b) and with a few
markers (Schneider-Stock et al, 2005; Sabah et al, 2006; Schmieder
et al, 2008). But the results are still in some cases contradictory,
and these alterations, not currently considered as established
independent prognostic factors, are not included in risk classifica-
tions. High-throughput gene expression profiling may improve the
prognostic classification of cancers, as observed in breast cancer
(Bertucci et al, 2006). Several DNA microarray-based studies of
GIST samples (Allander et al, 2001; Antonescu et al, 2004; Koon
et al, 2004; Subramanian et al, 2004; Kang et al, 2005; Yamaguchi
et al, 2008; Ostrowski et al, 2009; Rink et al, 2009; Astolfi et al,
*Correspondence: Professor F Bertucci;
E-mail: BERTUCCIF@ipc.unicancer.fr
Received 7 June 2012; revised 20 July 2012; accepted 6 August 2012;
published online 28 August 2012
British Journal of Cancer (2012) 107, 1433–1441
& 2012 Cancer Research UK All rights reserved 0007 – 0920/12
www.bjcancer.com
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
2010; Yang et al, 2010; Arne et al, 2011; Ylipaa et al, 2011; Lagarde
et al, 2012) have highlighted the transcriptional heterogeneity of
the disease, notably related to the location, the mutational status,
and the risk group. But these series are relatively small (60 cases
for the largest one), only 4 directly addressed the prognostic issue
(Koon et al, 2004; Yamaguchi et al, 2008; Arne et al, 2011; Lagarde
et al, 2012), and none identified a multigene predictor that was
tested in an independent validation set.
Here, we analysed expression data of 146 imatinib-untreated
localised GIST profiled using whole-genome DNA microarrays,
and searched for a GES predictive for RFS after surgery.
MATERIALS AND METHODS
Tumour samples
We collected from our databases (Kang et al, 2005; Ostrowski et al,
2009; Astolfi et al, 2010) and public databases (Yamaguchi et al,
2008; Rink et al, 2009; Lagarde et al, 2012) clinical and whole-
genome expression data of pre-treatment samples from 146
non-metastatic GIST patients (Kang et al, 2005; Yamaguchi et al,
2008; Ostrowski et al, 2009; Astolfi et al, 2010; Lagarde et al, 2012)
treated with complete primary surgery without adjuvant imatinib
(Table 1), and from 28 patients with advanced GIST treated with
neo-adjuvant imatinib in the Radiation Therapy Oncology Group
Study 0132 (RTOG0132; Rink et al, 2009). Data sets are described
in Supplementary Table S1. Samples were profiled using whole-
genome DNA microarrays: Affymetrix U133 Plus 2.0 (Yamaguchi
et al, 2008; Ostrowski et al, 2009; Astolfi et al, 2010), Agilent 44K
(Rink et al, 2009; Lagarde et al, 2012), and home-made
microarrays spotted at the Genome Institute of Singapore (Kang
et al, 2005). The study was approved by our Institutional Board.
Gene expression data analysis
Before analysis, we first re-annotated all hybridisation probes
present on the three types of microarrays (Affymetrix, Agilent, and
Singapore’s microarrays). Affymetrix gene chips annotations were
updated using NetAffx Annotation files (www.affymetrix.com;
release from 1 December 2008). Agilent gene chips annotations
were retrieved and updated using both SOURCE (http://smd.
stanford.edu/cgi-bin/source/sourceSearch) and EntrezGene (Homo
sapiens gene information database, release from 09 December
2008, ftp://ftp.ncbi.nlm.nih.gov/gene/). Regarding the Singapore
chips, the 18 664 probe sets representing 18 664 unique (LEADSt)
genes were updated using both SOURCE and EntrezGene.
All probes were thus mapped based on their EntrezGeneID. When
multiple probes were mapped to the same GeneID, the one with the
highest variance in a particular data set was selected to represent
the GeneID.
Data sets were then processed as follows. For the Agilent-based
sets and the Singapore set, we used the available processed data.
Regarding the Affymetrix-based data sets, we applied Robust
Multichip Average to the raw data before using distance weighted
discrimination to make each set comparable to each other using
the Yamaguchi’s set as reference. Robust Multichip Average was
done in R using Bioconductor (Seattle, WA, USA) and associated
packages.
Unsupervised hierarchical clustering was applied to Affymetrix
data only. Before clustering, a filtering retained the 12 619 genes
with the most variable expression across all samples (s.d.X0.25).
Clustering was done with the Cluster program (Eisen et al, 1998)
using Pearson’s uncentered correlation and centroid linkage
clustering. Results were displayed using TreeView program
(Eisen et al, 1998). Biologically relevant gene clusters were
identified and summarised as metagenes for prognostic analysis.
Metagene expression value was the mean of the normalised
expression values of all genes in the respective gene subset. Once
computed, the metagenes were tested as continuous value for their
prognostic incidence with respect to RFS using Cox regression
univariate and multivariate analyses.
Supervised analysis searched for a GES associated with RFS. The
data set was split into a learning set (64 Affymetrix samples;
Yamaguchi et al, 2008; Ostrowski et al, 2009; Astolfi et al, 2010)
and a validation set (82 independent, non-Affymetrix samples;
Kang et al, 2005; Rink et al, 2009; Lagarde et al, 2012). Cox
regression analysis (Wald test) was applied to the 17 870 genes
using a FDR threshold of 1% after adjustment for testing of
multiple hypotheses. The robustness of the signature was then
tested in the independent validation set: by classifying samples
according to the Pearson correlation coefficient of their expression
profile with the mean profile of the samples with relapse from the
learning set. The resulting gene list was interrogated using the
Ingenuity Pathway Analysis (IPA) software (Redwood City, CA,
USA) to assess significant representation of biological pathways
(thresholds of significance for P-values were 0.001).
We also tested the prognostic value of three proliferation-based
GES previously reported in breast cancer and soft tissue sarcoma:
the Genomic Grade Index (GGI), which includes 128 probe sets
(108 genes; Sotiriou et al, 2006), the 16-kinase signature
(16-Kinase), which includes 16 kinase genes (Finetti et al, 2008),
and the CINSARC signature, which includes 67 genes (Chibon
et al, 2010). Each signature was applied in each of the five data sets
separately to guarantee the largest number of common genes as
Table 1 Histoclinical characteristics of the 146 GIST samples
Characteristics (N) N (%)
Sex (146)
F 56 (38)
M 90 (62)
Age (86)
p60 38 (44)
460 48 (56)
Site (146)
G 116 (79)
SI 21 (14)
Other 9 (7)
Size (86)
p5 36 (42)
p10 32 (37)
410 18 (21)
AFIP (146)
Low 77 (53)
Intermediate 30 (21)
High 39 (27)
Mutation (145)
KIT_ex9 9 (6)
KIT_ex11 93 (64)
KIT_ex13 1 (1)
KIT_ex17 1 (1)
PDGFRA_ex12 5 (3)
PDGFRA_ex14 1 (1)
PDGFRA_ex18 18 (12)
Wild type 17 (12)
Relapse (146)
0 114 (78)
1 32 (22)
5 Year RFS (86) 79% (0.69–0.90)
Median follow-up, months (range) 47 (2–165)
Abbreviations: ex¼ exon; F¼ female; G¼ gastric; GIST¼ gastrointestinal stromal
tumour; M¼male; RFS¼ relapse-free survival; SI¼ small intestine.
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possible. We then strictly applied the same method (score or
correlation, cutoffs, and scaling methods) as that reported in the
original publications to classify each sample into the prognostic
group ‘low-risk’ or ‘high-risk’. More details are available in
Supplementary Table S2. Another supervised analysis comparing
the gene expression profiles of the two GGI-based sample groups
was done in the Affymetrix data set using significance analysis of
microarrays with a FDR threshold of 1%.
Statistical analyses
Correlations between sample groups and histoclinical factors were
calculated with the Fisher’s exact test for qualitative variables and
the Mann–Whitney test for continuous variables. The primary
endpoint was RFS calculated from the date of diagnosis until date
of first relapse whatever its location using the Kaplan–Meier
method. In one data set (Lagarde et al, 2012), the presence or
absence of relapse was documented without information about the
delay (60 samples). In the whole data set (N¼ 146), 114 patients
did not experience any relapse, whereas 32 relapsed. In the 86 cases
with available time information, the median follow-up – measured
from the date of diagnosis to the date of last news – was 47 months
(range, 2–165) for the 71 relapse-free patients; the median time to
relapse was 19 months (range, 5–74) for the 15 patients who
relapsed, and the 5-year RFS was 79% (CI 95% (69–90)). Survival
was compared between groups with the log-rank test. Univariate
and multivariate analyses were done using either Cox regression
analysis when the time information was available, or a logistic
regression analysis using the glm function (R’s statistical package)
when it was not available (significance estimated by specifying a
binomial family for model with a logit link). The variables tested in
univariate analyses included the sample classification based on
each GES ‘high-risk’ vs ‘low-risk’ and the AFIP classification (high
vs intermediate vs low-risk). Multivariate analysis incorporated all
variables with a P-value inferior to 1% in univariate analysis. The
Cox multivariate analysis was done with the Cox proportional
hazard model or Cox regression with the Firth’s correction
(R software, Bioconductor) depending on occurrence or not of
relapse in the reference group. All statistical tests were two-sided at
the 5% level of significance. Statistical analysis was done using the
survival package (version 2.30) in the R software (version 2.9.1).
The paper is written in accordance with reporting recommenda-
tions for tumour marker prognostic studies (REMARK) criteria
(McShane et al, 2005).
RESULTS
Whole-genome gene expression profiles
Hierarchical clustering was applied to 64 samples and 12 619 most
varying genes in the Affymetrix data set (Supplementary Figure
S1). As reflected by the dendrogram, the samples displayed
heterogeneous expression profiles (Supplementary Figures
S1A and B). They were sorted into two main 32 sample clusters
(I and II), which correlated with the anatomical site (69% gastric
in cluster I vs 100% in cluster II, P¼ 8.5E 04) and the
mutation status (84% KIT-mutated in cluster II vs 48% in cluster
I, and 3% PDGFRA-mutated in cluster II vs 29% in cluster I,
P¼ 3.2E 04). No significant correlation existed with the AFIP
classification or clinical outcome, even if cluster II included more
AFIP high-risk patients (34% vs 15% in cluster I; P¼ 0.17),
and more patients with relapse during follow-up (22% vs 9%;
P¼ 0.3; HR¼ 2.67).
Several gene clusters were evidenced. Some of them defined
expression signatures related to specific cell types, biological
functions, or chromosomal locations (Supplementary Figures
S1A–C). A proliferation cluster included two classical proliferation
markers (MKI67 and PCNA) and many genes involved in the cell
cycle and mitosis such as AURKA/B; cyclin genes, TOP2A, TTK, or
BUB1. Visually, this cluster was more expressed in AFIP high-risk
samples in agreement with a likely higher mitotic index.
An immune cluster reflected variation in specific immune cell
types within the tumours. It included genes encoding markers of B
cells (immunoglobulins and HLA molecules), T cells (CD3, ZAP70,
and CD4), NK cells (NKG7 and CD244), or macrophages (CD68,
CD14, and CSF1R). Visually, this cluster was more expressed in
PDGFRA-mutated samples in agreement with their classically high
lymphocyte infiltrate (Subramanian et al, 2004). An early response
gene cluster, including for example FOS, ATF3, DUSP2, and
NR4A2, appeared more expressed in PDGFRA-mutated samples as
expected (Subramanian et al, 2004). A cluster, enriched in genes
involved in angiogenesis (VEGFA, TEK, FLT1/3, CDH5, and
PECAM1) was overall overexpressed in samples without KIT exon
11 mutation as expected (Imamura et al, 2007). Finally, a cluster of
co-expressed genes represented a presumptive lost chromosomal
region (9p loss cluster, of which 15% of genes are located on the 9p
chromosomal arm); its expression was visually negatively
correlated with that of the ‘proliferation cluster’ and associated
with worse RFS as previously reported (Schneider-Stock et al,
2005; Haller et al, 2008a). We tested the prognostic value of these
five clusters computed as metagenes. The proliferation, 9p loss,
and early response metagenes were associated with poor RFS in
Cox univariate analysis (Po0.05, Wald test), whereas the two other
ones (immune and vascular) were not. In multivariate analysis
including the three significant metagenes, only the proliferation
metagene remained significant.
We also confirmed the overexpression of some individual
control genes in relation with the mutation status (Subramanian
et al, 2004; Chi et al, 2010; Arne et al, 2011): KIT, CD34, ETV1,
PROM1 (CD133), or RPS6KA1 in KIT-mutated samples, EPHA4 or
DSG2 for KIT exon 9 mutations, and PDGFRA, IGFBP5, IGF1,
SPON1, or PRKCA for PDGFRA mutations.
GES for RFS
We searched for a GES associated with RFS. The data set was split
into a learning set and a validation set. To avoid additional
normalisation, we used the Affymetrix set as learning set (N¼ 64)
and the two other sets as independent validation set (N¼ 82).
In the learning set (10 relapses), Cox analysis identified 275
discriminating genes (FDR 1%; Supplementary Table S3), includ-
ing 129 genes overexpressed and 146 underexpressed in samples
with event. As expected, the resulting classification of learning set
samples strongly correlated with clinical outcome (P¼ 8.5E 04,
Supplementary Figure S2A). More importantly, in the validation
set (Supplementary Figure S2B), 39 out of 60 (65%) patients who
did not relapse were classified by the signature as ‘low-risk’, and 21
out of 22 (95%) patients who relapsed were accurately predicted as
‘high-risk’. The rate of accurate classification was 73%, suggesting
the robustness of the signature (P¼ 5.4E 07). When applied to
the whole series of samples (learning and validation sets pooled),
71 out of 114 (63%) patients who did not relapse were classified as
‘low-risk’, and 31 out of 32 (97%) patients who relapsed were
accurately predicted as ‘high-risk’ (P¼ 3.7E 10). Considering the
86 patients with available RFS time, the 5-year RFS was 97% (CI
95% (92–100)) in the ‘low-risk’ group (N¼ 39) and 64% (CI 95%
(50–84)) in the ‘high-risk’ group (N¼ 47) as defined using the
signature (P¼ 0.0016, Figure 1A).
The biological significance of the signature was interrogated
using the IPA gene ontology software (Supplementary Table S4A).
No significantly enriched canonical pathway was identified for the
146 underexpressed genes. By contrast, analysis found a significant
overrepresentation of cell cycle-associated pathways within the
overexpressed genes.
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Prognostic value of three proliferation-based GES
Given the importance of proliferation genes in this signature, we
tested whether three published proliferation-associated GES with
prognostic value in breast cancer (GGI, 16-Kinase signature) and
sarcomas (CINSARC) had prognostic value in GISTs. Analysis was
done in two separated test sets (no. 1 and no. 2). We first analysed
the 86 sample series (test set no. 1) where the time to RFS was
available. Each GES divided samples into two groups ‘low-risk’ and
‘high-risk’ with different 5-year RFS (Figures 1B–D), respectively,
91% (CI 95% (82–100); N¼ 66) and 46% (CI 95% (28–77); N¼ 20)
with the GGI (P¼ 1.4E 06), 93% (CI 95% (85–100); N¼ 51) and
59% (CI 95% (42–84); N¼ 35) with the 16-Kinase signature
(P¼ 6.44E 04), and 92% (CI 95% (84–100); N¼ 48) and 67%
(CI 95% (53–86); N¼ 38) with CINSARC (P¼ 0.01). Table 2 shows
the corresponding contingency tables. Although each signature
gave significant results, the largest difference in RFS was observed
with the GGI.
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Figure 1 Time-dependent correlation between the classifications based on four prognostic GES and RFS in 86 GIST samples. Kaplan–Meier RFS curves of
the two GIST groups (low-risk and high-risk) defined by the: (A) 275-gene signature, (B) GGI, (C) 16-Kinase signature, and (D) CINSARC.
Table 2 Correlation between the classifications based on three prognostic GES and RFS in GIST samples in the two tests sets, separately and pooled
Test set no. 1
(N¼ 86; time to RFS available)
Test set no. 2
(N¼ 60; time to RFS not available)
Pooled test sets
(N¼ 146; all samples)
Prognostic
Relapse
P-valuea
Relapse
P-valuea
Relapse
P-valuea
GES No Yes Total OR (95% CI) No Yes Total OR (95% CI) No Yes Total OR (95% CI)
GGI
Low-risk 62 4 66 5.83E 06 42 4 46 5.94E 09 104 8 112 3.70E 13
High-risk 9 11 20 17.9 (4.2–94.8) 1 13 14 114.2 (12.5–5653.5) 10 24 34 29.8 (10.0–100.2)
16-Kinase
Low-risk 48 3 51 1.04E 03 33 1 34 4.75E 07 81 4 85 3.77E 09
High-risk 23 12 35 8.1 (1.9–49.3) 10 16 26 48.75 (6.2–2246.3) 33 28 61 16.8 (5.3–71.1)
CINSARC
Low-risk 45 3 48 3.34E 03 32 0 32 5.54E 08 77 3 80 2.30E 09
High-risk 26 12 38 6.8 (1.6–40.8) 11 17 28 INF (9.4–Inf) 37 29 66 19.7 (5.6–107.7)
Abbreviations: CI¼ confidence interval; CINSARC¼ complexity index in sarcomas; GES¼ gene expression signature; GGI¼Genomic Grade Index; GIST¼ gastrointestinal
stromal tumour; OR¼ odds ratio; RFS¼ relapse-free survival. aFisher’s exact test P-value with OR and CI associated.
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For further validation in an independent set, we repeated the
analysis in the 60 Lagarde’s samples. In this series, the time to
relapse was not available (test set no. 2). The correlation between
the resulting classification and the survival was thus analysed
using contingency tables (Table 2). Correlation was significant for
each signature, but again stronger for the GGI. When we pooled
the two test sets (N¼ 146), the rate of accurate classifications
was 88% for GGI, 75% for the 16-Kinase signature, and 73%
for CINSARC (Table 2). We thus focused on the GGI in the next
sections.
Univariate and multivariate analyses for RFS
We compared the prognostic performances of the classifications
based on the 275-gene GES, GGI, and AFIP (Table 3). Analysis was
done in the two test sets, separately then pooled.
In the test set no. 1 (86 samples with available time to RFS) Cox
univariate analysis confirmed the prognostic value of the three
classifiers. In multivariate analysis, the GGI and the AFIP high-risk
classification remained significant, suggesting their independent
prognostic value, but the AFIP intermediate-risk classification was
not. Genomic Grade Index sorted the AFIP intermediate/high-risk
samples into two groups ‘low-risk’ and ‘high-risk’ with respective
5-year RFS of 73% (CI 95% (52–100); N¼ 22) and 35% (CI 95%
(17–70); N¼ 16; P¼ 8.5E 03; Figure 2).
As independent validation, we repeated the analyses in the test
set no. 2 (Lagarde’s 60 sample series) using logistic regression.
Results of univariate analysis were similar. In multivariate analysis,
the GGI signature remained significant, whereas the AFIP
intermediate-risk classification was not. Genomic Grade Index
sorted the AFIP intermediate/high-risk samples into two groups
with different relapse rate: 4 out of 17 patients (24%) in the
‘low-risk’ group and 13 out of 14 (93%) in the ‘high-risk’
(OR¼ 35.7; P¼ 1.8E 04). When we pooled the two test sets
(N¼ 146), similar results were observed (Table 3).
Table 3 Univariate and multivariate analyses for RFS
Univariate:
Cox regression
Multivariate: Cox regression using
Firth’s bias reduction
Test set no. 1 (N¼ 86; time to RFS available) N HR (95% CI) P-value N HR (95% CI) P-value
GGI
High vs low 86 9.93 (3.13–32.3) 2.12E 05 86 3.23 (1.12–10.83) 2.91E 02
AFIP
Intermediate vs low 86 3.84E08 (0–Inf) 3.38E 08 86 11.2 (0.87–1.6E03) 0.06
High vs low 86 2.17E09 (0–Inf) 86 44.1 (5.23–5.8E03) 3.01E 05
275-gene
Poor vs good 86 12.64 (1.66–96.17) 1.43E 02
Univariate: logistic regression Multivariate: logistic regression
Test set no. 2 (N¼ 60; time to RFS not available) N Coefficient P-value N Coefficient P-value
GGI
High vs low 60 0.84 1.19E 13 60 0.60 3.16E 08
AFIP
Intermediate vs low 60 0.29 9.17E 03 60 0.11 0.19
High vs low 60 0.78 8.13E 11 60 0.41 5.83E 05
275-gene
Poor vs good 60 0.63 1.22E 09 60 0.27 7.14E 04
Univariate: logistic regression Multivariate: logistic regression
Pooled test sets (N¼146; all samples) N Coefficient P-value N Coefficient P-value
GGI
High vs low 146 0.63 o2.00E 16 146 0.35 1.25E 07
AFIP
Intermediate vs low 146 0.20 o2.00E 16 146 0.12 0.05
High vs low 146 0.67 8.13E 11 146 0.42 1.75E 10
275-gene
Poor vs good 146 0.41 3.62E 10 146 0.15 2.88E 03
Abbreviations: CI¼ confidence interval; GGI¼Genomic Grade Index; HR¼ hazard ratio; RFS¼ relapse-free survival.
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Figure 2 Correlation between the GGI-based classification and RFS in
the AFIP intermediate/high-risk GIST samples. Kaplan–Meier RFS curves in
the patients with available RFS time (N¼ 38).
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Comparison of the two GGI-based GIST groups
The GGI was thus an independent predictor for RFS in two
independent GIST tests sets. To explore the differences between
the so-defined GGI ‘low-risk’ and ‘high-risk’ groups, we compared
their histoclinical features (N¼ 146; Supplementary Table S5).
Significant differences existed for three parameters. Genomic
Grade Index ‘high-risk’ samples were more frequently AFIP high-
risk (P¼ 1.0E 05) and superior to 10 cm (P¼ 1.22E 04), and
displayed more relapses (P¼ 3.6E 13: OR¼ 29.84) despite a
similar follow-up. The AFIP intermediate/high-risk samples were
sorted by GGI into two groups with different rate of relapses: 8 out
of 39 patients (21%) in the ‘low-risk’ group and 24 out of 30 (80%)
in the ‘high-risk’ group (OR¼ 14.7; P¼ 8.8E 07).
We then compared the whole-genome expression profiles of the
two groups in the Affymetrix 64 sample series. Significance
analysis of microarrays analysis identified 254 discriminating
genes (FDR 1%), including 192 genes overexpressed and 62
underexpressed in the ‘high-risk’ samples (Supplementary Table
S6). Ontology analysis found an overrepresentation of canonical
pathways within the overexpressed genes only (Supplementary
Table S4B). Most of them were associated with cell cycle control
and genome stability: examples include ‘mitotic roles of polo-like
kinase’, ‘role of chk proteins in cell cycle checkpoint control’,
‘cell cycle: G2/M DNA damage checkpoint regulation’, or ‘cell cycle
control of chromosomal replication’. Of note, 10 out of the
16 significant pathways (62.5%) were common to those identified
by IPA analysis of the genes overexpressed in the 275-gene GES.
GGI-based classification and response to imatinib
A major and complementary issue is to determine whether the GGI
‘high-risk’ patients are more sensitive to imatinib. We analysed a
set of 28 pre-treatment samples from patients with advanced
primary and recurrent operable GIST treated in a phase II trial
(RTOG0132) with 8–12 weeks neo-adjuvant imatinib and for whom
the degree of clinical response (RECIST by comparing tumour
measurements on computed tomography scans before and
after imatinib) was available (Rink et al, 2009). The percentage
of tumour shrinkage ranged from  76 to þ 21%.
We reproduced the two GGI-based groups. As expected given
the advanced stage of disease, more patients were classified
as ‘high-risk’ (N¼ 24) than ‘low-risk’ (N¼ 4). Despite the low
number of samples, the correlation between those groups and the
degree of response (continuous variable) was significant with
greater tumour shrinkage in the ‘high-risk’ group than the ‘low-
risk’ group (mean  29% vs  5%, P¼ 0.04; Figure 3). By applying
the response definition used in the original paper (binary
variable), the correlation was high, even if not significant owing
to the number of cases: 17 out of 24 ‘high-risk’ samples (71%) were
classified as rapid responders, whereas 3 out of 4 ‘low-risk’
samples (75%) as non-responders (P¼ 0.116), with a OR for
response of 6.7 in the ‘high-risk’ group as compared with the ‘low-
risk’ group. These results suggested that GGI ‘high-risk’ patients
are more imatinib sensitive than are ‘low-risk’ patients.
DISCUSSION
The risk of postoperative relapse in GIST patients dictates the
delivery or not of adjuvant imatinib and the follow-up. Risk
stratification systems based on histoclinical features exist, but are
not perfect to solve the actual prognostic heterogeneity of disease.
In Europe, the current gold standard is the AFIP classification and
all intermediate- or high-risk patients are candidate to imatinib
although many of them are in fact cured by surgery alone and do
not need any postoperative therapy. Better identifying them would
avoid not only the imatinib-related toxicity, but also the financial
cost related to at least 1–3 years of treatment. Efforts are ongoing
to improve these stratification systems (Gold et al, 2009; Patel,
2011; Rossi et al, 2011; Joensuu et al, 2012). Although GIST is the
most frequent digestive sarcoma, it has been only recently defined
as an entity and the research on DNA microarrays and GIST
prognosis has suffered from a lack of large clinically documented
series (60 cases for the largest one), impeding the use of
independent learning and validation sets. We analysed gene
expression and histoclinical data of 146 localised GIST operated
and untreated with adjuvant imatinib to assess the prognostic
performance of gene expression profiles. To our knowledge, this is
the largest series reported to date, and the first one that includes
independent validation.
Unsupervised analysis confirmed the transcriptional hetero-
geneity of disease and expression differences associated with the
mutation status. Supervised analysis searched for a GES associated
with RFS. As recommended, our data set was split into two sets,
learning and validation sets. We identified a 275-gene GES
associated with RFS in a learning set and validated its robustness
in an independent validation set. As this GES was mainly driven by
proliferation genes, we hypothesised that three robust prognostic
signatures associated with cell cycle control might be predictive for
RFS in GIST. These signatures had been identified using
hypothesis-driven approaches in breast cancer (by comparing
histological grade III vs I for GGI, and basal vs luminal subtype for
the 16-Kinase) and in sarcoma (CINSARC by comparing samples
with high vs low number of genomic alterations and high vs low
histological grade). Of note, none of the GIST samples had been
used to generate these signatures. However, we divided our data
set in two independent test sets, and interestingly, each signature
had a prognostic value in each set. As GGI was the most significant
one, we compared its prognostic performances with those of the
275-gene GES and the AFIP classification. We found that GGI and
the AFIP high-risk classification were independent prognosticators
in both test sets. Genomic Grade Index provided additional
information to AFIP by discriminating within the intermediate/
high-risk AFIP patients those with good prognosis GGI ‘low-risk’,
who are not likely to need adjuvant imatinib, from those with
poor prognosis GGI ‘high-risk’, who likely need imatinib.
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Figure 3 Correlation between the GGI-based classification and
the response to neo-adjuvant imatinib. Correlation between the two
GGI-based groups (high-risk and low-risk; N¼ 29) and the response to
imatinib assessed as a continuous variable (box plot). The horizontal
dashed line indicates the cutoff of tumour shrinkage that defines the
responder status. The figures within the box plot indicate the number of
patients in each of the four categories.
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Interestingly, we showed in a series of patients treated with
neo-adjuvant imatinib for primary GIST (Rink et al, 2009) that
GGI ‘high-risk’ patients were more frequently rapid responders to
imatinib than ‘low-risk’ patients. If confirmed in a larger series,
this correlation would further increase the clinical interest of
GGI in GIST.
Ontologies associated with the genes discriminating the two
GGI-based groups showed that the poor prognosis of ‘high-risk’
group was mainly related to alterations in cell cycle control and
maintenance of genome stability, these tumours being more
proliferative and more unstable at the chromosomal level. This
was confirmed using GSEA and a GES of genome instability
(Carter et al, 2006; normalised enrichment score¼ 1.86,
Po2.12E 16; data not shown). This higher instability likely
confers to ‘high-risk’ tumours the ability to accumulate molecular
alterations allowing them to metastasise. The prognostic impor-
tance of proliferation in GIST is well known. The mitotic index is a
component of current risk stratifications systems, but is liable to
interobserver and technical variability (Patel, 2011). The prog-
nostic value of expression of cell cycle-regulatory genes has been
reported (Haller et al, 2005; Schneider-Stock et al, 2005; Sabah
et al, 2006; Schmieder et al, 2008; Haller et al, 2008a, b; Romeo
et al, 2009; Dorn et al, 2010; Fujita et al, 2012; Okamoto et al,
2012). To date, four studies have analysed the prognostic value of
gene expression profiles (Koon et al, 2004; Yamaguchi et al, 2008;
Arne et al, 2011; Lagarde et al, 2012), but the largest one included
60 cases only. Here, using a stringent significance threshold and in
our 146 sample series, CCNB1 and CENPF (Koon et al, 2004) were
included in our 275-gene list, but CD133 (Arne et al, 2011) and
CD26 (Yamaguchi et al, 2008) were not; however, CD26 expression
was associated with RFS (P¼ 0.0085) using less stringent criteria.
Recently, Lagarde et al (2012) showed the prognostic value of
CINSARC and AURKA expression, and developed a Genomic
Index defined upon array-CGH data as a score of genomic
instability associated with metastasis-free survival. Unfortunately,
this prognosticator was not validated by the authors in an
independent sample set. Here, we confirmed the prognostic value
of CINSARC, but showed that GGI was a stronger prognosticator
in two independent test sets.
Several genes included in the GGI and/or overexpressed in the
GGI ‘high-risk’ samples encode potential therapeutic targets
involved in cell cycle regulation that could be, if functionally
validated, targeted by new drugs in the adjuvant setting, alone or
associated with imatinib: kinases (AURKA/B, BUB1, CDC2, CDK4,
CHEK1, NEK2, and PLK1/4) and phosphatase (CDC25). Corre-
sponding inhibitors have entered cancer clinical trials with
promising results.
In conclusion, we show that a GGI-based classification of
operated GIST outperforms the prognostic performances of three
other GES and the AFIP intermediate-risk classification. The
strength of our results lies in the size of our series (the largest one
reported so far), the biological relevance of GGI, its independent
prognostic value in two independent test sets through three
different technological platforms. Of note, GGI sorts the AFIP
intermediate/high-risk samples – current candidate to adjuvant
imatinib – into two groups with different RFS. ‘High-risk’ tumours
according to GGI are more proliferative and genetically unstable
than ‘low-risk’ tumours, and more rapidly sensitive to imatinib. By
refining the prediction of RFS, GGI might improve our ability to
better tailor adjuvant imatinib. Further clinical validation of GGI is
warranted in larger retrospective, then prospective series, as well
as the functional validation of relevant genes that could provide
new therapeutical targets.
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